Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 3/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4398757 | 1.00 | MME (0.53) | MMEL3MBTL1NPSR1PTPN1NAALAD2 | |
| SCHEMBL3626589 | 0.86 | FOLH1 (0.52) | MMEL3MBTL1NAALAD2 | |
| SCHEMBL3626583 | 0.86 | FOLH1 (0.52) | MMEL3MBTL1NAALAD2 | |
| SCHEMBL1151 | 0.86 | FOLH1 (0.52) | MMEL3MBTL1NAALAD2 | |
| SCHEMBL19521372 | 0.86 | FOLH1 (0.52) | MMEL3MBTL1NAALAD2 | |
| SCHEMBL7274 | 0.86 | FOLH1 (0.52) | MMEL3MBTL1NAALAD2 | |
| SCHEMBL476018 | 0.86 | GPR34 (0.62) | MMEMMP9 | |
| SCHEMBL476020 | 0.86 | GPR34 (0.62) | MMEMMP9 | |
| Phosphoric Acid SCHEMBL3476884 | 0.85 | FOLH1 (0.51) | MMEL3MBTL1NAALAD2 | |
| SCHEMBL19615881 | 0.85 | FOLH1 (0.51) | MMEL3MBTL1NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240358867-A1 | REAGENTS FOR SITE-SPECIFIC LABELING OF PROTEINS WITH RADIOHALOGENS, AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2024-10-31 | — | — | US | claimed |
| EP-4395834-A1 | REAGENTS FOR SITE-SPECIFIC LABELING OF PROTEINS WITH RADIOHALOGENS, AND METHODS OF MAKING AND USING THE SAME | Duke University (US) | 2024-07-10 | — | — | EP | claimed |
| CN-118176024-A | Reagents for site-specific labelling of proteins with radiohalogen, and methods of making and using the same | 杜克大学 | 2024-06-11 | — | — | CN | claimed |
| WO-2023034450-A1 | REAGENTS FOR SITE-SPECIFIC LABELING OF PROTEINS WITH RADIOHALOGENS, AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2023-03-09 | — | — | WO | claimed |
| US-6307090-B1 | OXALYL ENDCAPPED; CONTAINING A BIVALENT RADICAL OF PHOSPHOTYROSINE OR A PHOSPHOTYROSINE MIMETIC | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-10-23 | — | — | US | claimed |
| US-20240358867-A1 | REAGENTS FOR SITE-SPECIFIC LABELING OF PROTEINS WITH RADIOHALOGENS, AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2024-10-31 | — | — | US | disclosed |
| EP-4395834-A1 | REAGENTS FOR SITE-SPECIFIC LABELING OF PROTEINS WITH RADIOHALOGENS, AND METHODS OF MAKING AND USING THE SAME | Duke University (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118176024-A | Reagents for site-specific labelling of proteins with radiohalogen, and methods of making and using the same | 杜克大学 | 2024-06-11 | — | — | CN | disclosed |
| EP-3551214-B1 | TREATMENT OF OBESITY AND EATING DISORDERS | ST VINCENTS HOSPITAL SYDNEY LTD (AU) | 2024-03-13 | — | — | EP | disclosed |
| US-11702457-B2 | Agent and method for enhancing fertility | MONASH UNIVERSITY (AU) | 2023-07-18 | — | — | US | disclosed |
| CN-110072541-B | Treatment of obesity and eating disorders | 圣文森特医院悉尼有限公司 | 2023-05-02 | — | — | CN | disclosed |
| WO-2023034450-A1 | REAGENTS FOR SITE-SPECIFIC LABELING OF PROTEINS WITH RADIOHALOGENS, AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2023-03-09 | — | — | WO | disclosed |
| EP-1169470-B1 | METHODS AND REAGENTS FOR DETERMINING ENZYME SUBSTRATE SPECIFICITY, AND USES RELATED THERETO | TUFTS COLLEGE (US) | 2004-06-23 | — | — | EP | disclosed |
| EP-1169470-A1 | METHODS AND REAGENTS FOR DETERMINING ENZYME SUBSTRATE SPECIFICITY, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2002-01-09 | — | — | EP | disclosed |
| US-6307090-B1 | OXALYL ENDCAPPED; CONTAINING A BIVALENT RADICAL OF PHOSPHOTYROSINE OR A PHOSPHOTYROSINE MIMETIC | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-10-23 | — | — | US | disclosed |
| WO-2000061789-A1 | METHODS AND REAGENTS FOR DETERMINING ENZYME SUBSTRATE SPECIFICITY, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2000-10-19 | — | — | WO | disclosed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
| WO-1997007131-A1 | ACYLATED OLIGOPEPTIDES CONTAINING PHOSPHOTYROSINE AS INHIBITORS OF PROTEIN TYROSINE KINASES | NOVARTIS AG (CH) | 1997-02-27 | — | — | WO | disclosed |
| WO-1994007913-A1 | PEPTIDE ANTAGONISTS OF SH2 BINDING AND THERAPEUTIC USES THEREOF | WARNER-LAMBERT COMPANY (US) | 1994-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240358867-A1 | REAGENTS FOR SITE-SPECIFIC LABELING OF PROTEINS WITH RADIOHALOGENS, AND METHODS OF MAKING AND USING THE SAME | CDC73, MYCBP, TP53 | MME 1063/4885L3MBTL1 908/4885NPSR1 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.